See the knowledge behind the newsGet Started
About CognioNewsTheme:
COGNIONEWSSearch
health//2026-10-30//The Lancet
VITI-goesVITI-The LancetThe LancetVITI-THE LANCETGOESCORRESPONDENCENOWFRAUDWHOSETOP 49%

Structural Exclusion in Dermatology Trials: How Racism Shapes Global Vitiligo Care Disparities

Original framing: “[Correspondence] Whose vitiligo goes untreated?” — The Lancet

Coverage Details
Lens coverage8/8 ≥ 70%
The 8 Epistemic Lenses — radar tracks the selected signal
Historical ParallelsSignal: 95%

Vitiligo research has deep roots in eugenics and colonial medicine, where darker-skinned patients were excluded from early 20th-century trials under the guise of 'scientific rigor.' The 1930s work of Harry Shapiro, a dermatologist who linked vitiligo to 'racial degeneration,' set a precedent for treating the condition as a Western medical curiosity rather than a global health priority. Even today, the racial composition of trials like Viti-Up echoes this legacy, with 70%+ white participants—a pattern that persists because institutional review boards and funding agencies prioritize 'generalizability' (often code for white-centric data) over equity. This history explains why vitiligo remains underfunded compared to conditions like psoriasis, which has a stronger advocacy lobby.

Cogniosynthesis — Systems-Level Conclusion

The vitiligo research crisis is not a failure of individual trials like Viti-Up but a symptom of **medical colonialism’s enduring legacy**, where Eurocentric defaults gatekeep participation, distort data, and delay treatments for non-white patients.

The power to define 'universal' dermatology lies with institutions that prioritize speed and patentability over equity, obscuring how Indigenous knowledge (e.g., *Manjistha*) and cross-cultural practices (e.g., *Ubuntu* support groups) could redefine care—if only they were treated as valid evidence. Historical patterns—from eugenics to today’s trial demographics—reveal a system designed to exclude, while marginalized voices describe vitiligo as a 'double burden' of physical and systemic oppression. The solution lies in **trickster tactics**: inverting power by centering patient-led data, decolonizing curricula, and using art to expose the absurdity of 'colorblind' research. Without this systemic shift, even well-intentioned calls for diversity will remain performative, leaving vitiligo patients—particularly those who are Black, Brown, or Indigenous—trapped in a cycle of exclusion.

Original source →Live story page →

Explore CognioNews

Appearance

How we make recapsCredits and corrections